https://staging.xgeneconsulting.com/frequently-asked-questions/ 2026-07-23T16:11:13+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/what-should-leadership-do-in-the-first-72-hours-after-receiving-an-fda-form-483/ 2026-07-23T16:11:07+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/is-the-fastest-fda-483-response-usually-the-strongest-response/ 2026-07-23T16:11:07+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/what-is-the-difference-between-a-correction-an-interim-control-a-root-cause-a-capa-and-a-retrospective-review/ 2026-07-23T16:11:08+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/why-do-some-regulatory-deficiency-responses-close-the-issue-while-others-lead-to-more-questions/ 2026-07-23T16:11:08+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/what-does-fda-expect-from-an-oos-investigation-beyond-the-initial-laboratory-assessment/ 2026-07-23T16:11:09+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/how-is-capa-effectiveness-different-from-simply-closing-a-capa/ 2026-07-23T16:11:09+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/what-should-a-data-integrity-remediation-program-include-beyond-audit-trail-review/ 2026-07-23T16:11:09+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/what-should-a-regulated-company-evaluate-under-eu-annex-11-besides-electronic-signatures-and-audit-trails/ 2026-07-23T16:11:10+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/what-should-the-drug-product-quality-overall-summary-explain-beyond-the-composition-table/ 2026-07-23T16:11:11+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/how-can-a-company-make-its-cmc-knowledge-more-structured-reusable-and-ai-ready/ 2026-07-23T16:11:11+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/where-can-ai-be-used-responsibly-in-cmc-and-gmp-work-today/ 2026-07-23T16:11:12+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/when-should-a-sponsor-consider-a-type-b-meeting-or-other-formal-regulatory-interaction/ 2026-07-23T16:11:12+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/do-you-support-early-stage-companies-as-well-as-established-manufacturers/ 2026-07-23T16:11:12+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/how-does-xgene-begin-a-consulting-engagement/ 2026-07-23T16:11:13+00:00 https://staging.xgeneconsulting.com/frequently-asked-questions/does-xgene-only-write-regulatory-responses-and-cmc-documents-or-can-it-support-implementation/ 2026-07-23T16:11:13+00:00